Tendering and biosimilars: what role for value-added services?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

16 citing papers in PubMed.

1. Application of Actor Network Theory to Evaluate Supply and Demand Strategies Used to Encourage International Biosimilar Uptake.Pharmaceutical medicine · 2026
   Review
2. Creating A Multi-Criteria Decision Analysis Tool to Enhance Value-Based Purchasing of Generic and Biosimilar Medications in Saudi Arabia: A Pilot Study.ClinicoEconomics and outcomes research : CEOR · 2026
   Article
3. Demand- Versus Supply-Side Policies in Market Penetration of Biosimilars: Which is More Effective?BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025
   Article
4. Biosimilar Policies and Their Impact on Market Penetration of Adalimumab, Etanercept and Infliximab: A Policy Synthesis and Descriptive Analysis in 13 OECD Countries.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025
   Article
5. Beyond cost: a value-based framework for biosimilar procurement in emerging markets - the Thai experience.Journal of pharmaceutical policy and practice · 2025
   Article
6. Biosimilars in the Era of Artificial Intelligence-International Regulations and the Use in Oncological Treatments.Pharmaceuticals (Basel, Switzerland) · 2024
   Review
7. Fostering healthcare system sustainability through efficient practices: Can adopting biosimilars ease the financial burden of rheumatoid arthritis?F1000Research · 2024
   Review
8. The impact of EU public procurement regulations on tenders in Spain: a study with adalimumab.Frontiers in pharmacology · 2024
   Article
9. A concept for multi-winner tenders for medicinal products with balancing between efficient prices, long-term competition and sustainability of supply.Frontiers in medicine · 2023
   Article
10. How to select a best-value biological medicine? A practical model to support hospital pharmacists.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2022
    Article
11. Competitive tenders on analogue hospital pharmaceuticals in Denmark 2017-2020.Journal of pharmaceutical policy and practice · 2022
    Article
12. Emerging role of biosimilars in the clinical care of inflammatory bowel disease patients.World journal of clinical cases · 2022
    Review
13. Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?Drugs · 2021
    Review
14. Off-Patent Biologicals and Biosimilars Tendering in Europe-A Proposal towards More Sustainable Practices.Pharmaceuticals (Basel, Switzerland) · 2021
    Article
15. European Stakeholder Learnings Regarding Biosimilars: Part II-Improving Biosimilar Use in Clinical Practice.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2020
    Article
16. Economic evaluation of biosimilars for reimbursement purposes - what, when, how?Journal of market access & health policy · 2020
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as